Comparative Pharmacology
Head-to-head clinical analysis: BENZEDRINE versus EVEKEO ODT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENZEDRINE versus EVEKEO ODT.
BENZEDRINE vs EVEKEO ODT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Benzedrine (racemic amphetamine) releases dopamine and norepinephrine from presynaptic neurons, blocks their reuptake, and inhibits monoamine oxidase, increasing synaptic monoamine levels.
EVEKEO ODT (amphetamine) is a CNS stimulant that increases extracellular levels of dopamine and norepinephrine by blocking their reuptake into presynaptic neurons and inhibiting monoamine oxidase, leading to enhanced neurotransmission.
Oral: 5-10 mg once or twice daily, maximum 40 mg/day. Intramuscular: 5-10 mg every 30-60 minutes as needed, maximum 40 mg/day.
0.25 mg orally as a single dose; may repeat once after 30 minutes if required.
None Documented
None Documented
Terminal elimination half-life: 4-6 hours in adults (range 4-8 hours). Clinically, duration of action correlates with half-life, but tolerance may develop with repeated dosing.
3-5 hours in healthy adults; prolonged in renal impairment (up to 20 hours in ESRD)
Renal (30-40% unchanged, pH-dependent), with minor biliary/fecal elimination. At acidic urine pH, elimination half-life is shortened; at alkaline pH, reabsorption increases.
Renal: approximately 50% as unchanged drug and metabolites; fecal: minimal (<10%)
Category C
Category C
CNS Stimulant
CNS Stimulant